trying...
27096319 2016 09 26 2021 01 08 1097-4180 44 4 2016 Apr 19 Immunity Immunity Brain Endothelial- and Epithelial-Specific Interferon Receptor Chain 1 Drives Virus-Induced Sickness Behavior and Cognitive Impairment. 901 912 901-12 10.1016/j.immuni.2016.04.005 S1074-7613(16)30110-8 Sickness behavior and cognitive dysfunction occur frequently by unknown mechanisms in virus-infected individuals with malignancies treated with type I interferons (IFNs) and in patients with autoimmune disorders. We found that during sickness behavior, single-stranded RNA viruses, double-stranded RNA ligands, and IFNs shared pathways involving engagement of melanoma differentiation-associated protein 5 (MDA5), retinoic acid-inducible gene 1 (RIG-I), and mitochondrial antiviral signaling protein (MAVS), and subsequently induced IFN responses specifically in brain endothelia and epithelia of mice. Behavioral alterations were specifically dependent on brain endothelial and epithelial IFN receptor chain 1 (IFNAR). Using gene profiling, we identified that the endothelia-derived chemokine ligand CXCL10 mediated behavioral changes through impairment of synaptic plasticity. These results identified brain endothelial and epithelial cells as natural gatekeepers for virus-induced sickness behavior, demonstrated tissue specific IFNAR engagement, and established the CXCL10-CXCR3 axis as target for the treatment of behavioral changes during virus infection and type I IFN therapy. Copyright © 2016 Elsevier Inc. All rights reserved. Blank Thomas T Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany. Detje Claudia N CN Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Medical School Hannover, 30625 Hannover, Germany. Spieß Alena A Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany. Hagemeyer Nora N Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany. Brendecke Stefanie M SM Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany. Wolfart Jakob J Oscar Langendorff Institute of Physiology, University of Rostock, 18057 Rostock, Germany. Staszewski Ori O Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany. Zöller Tanja T Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany. Papageorgiou Ismini I Institute of Physiology and Pathophysiology, University of Heidelberg, 69120 Heidelberg, Germany. Schneider Justus J Institute of Physiology and Pathophysiology, University of Heidelberg, 69120 Heidelberg, Germany. Paricio-Montesinos Ricardo R Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany. Eisel Ulrich L M UL Department of Molecular Neurobiology, Groningen Institute of Evolutionary Life Sciences, University of Groningen, and Department of Psychiatry, University Medical Center Groningen, 9700 Groningen, The Netherlands. Manahan-Vaughan Denise D Ruhr University Bochum, Medical Faculty, Department Neurophysiology, 44780 Bochum, Germany. Jansen Stephan S Ruhr University Bochum, Medical Faculty, Department Neurophysiology, 44780 Bochum, Germany. Lienenklaus Stefan S Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Medical School Hannover, 30625 Hannover, Germany; Institute for Laboratory Animal Science, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. Lu Bao B Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Imai Yumiko Y Department of Biological Informatics and Experimental Therapeutics, Akita University Graduate School of Medicine, Akita 010-8543, Japan. Müller Marcus M Department of Neurology, Universitätsklinikum Bonn, 53105 Bonn, Germany. Goelz Susan E SE Portland, Oregon, 97201, USA. Baker Darren P DP Biogen Inc., Cambridge, MA 02142, USA. Schwaninger Markus M Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, 23538 Lübeck, Germany. Kann Oliver O Institute of Physiology and Pathophysiology, University of Heidelberg, 69120 Heidelberg, Germany. Heikenwalder Mathias M Institute of Virology, Technische Universität München/ Helmholtz-Zentrum München, 81756 München, Germany; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. Kalinke Ulrich U Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Medical School Hannover, 30625 Hannover, Germany. Prinz Marco M Institute of Neuropathology, University of Freiburg, 79106 Freiburg, Germany; BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany. Electronic address: marco.prinz@uniklinik-freiburg.de. eng GEO GSE74063 Journal Article Research Support, Non-U.S. Gov't United States Immunity 9432918 1074-7613 0 Adaptor Proteins, Signal Transducing 0 Chemokine CXCL10 0 Cxcl10 protein, mouse 0 Cxcr3 protein, mouse 0 IPS-1 protein, mouse 0 Ifnar1 protein, mouse 0 Interferon Type I 0 RNA, Double-Stranded 0 Receptors, CXCR3 156986-95-7 Receptor, Interferon alpha-beta EC 3.6.1.- Ddx58 protein, mouse EC 3.6.1.- Ifih1 protein, mouse EC 3.6.4.13 DEAD Box Protein 58 EC 3.6.4.13 DEAD-box RNA Helicases EC 3.6.4.13 Interferon-Induced Helicase, IFIH1 IM Immunity. 2016 Apr 19;44(4):718-20. doi: 10.1016/j.immuni.2016.03.010 27096312 Adaptor Proteins, Signal Transducing metabolism Animals Brain cytology immunology Cell Communication immunology Cells, Cultured Chemokine CXCL10 immunology Cognition Disorders genetics psychology DEAD Box Protein 58 DEAD-box RNA Helicases metabolism Endothelial Cells immunology Endothelium cytology immunology Epithelial Cells immunology Epithelium immunology Illness Behavior physiology Interferon Type I therapeutic use Interferon-Induced Helicase, IFIH1 Male Mice RNA, Double-Stranded genetics Receptor, Interferon alpha-beta genetics immunology Receptors, CXCR3 immunology Signal Transduction immunology Virus Diseases immunology CXCL10 CXCR3 IFN IFNAR1 IPS-1 MAVS behavior brain depression endothelia epithelia influenza neurons signal transduction type I interferon virus infection 2014 11 3 2015 10 19 2016 1 5 2016 4 21 6 0 2016 4 21 6 0 2016 9 27 6 0 ppublish 27096319 10.1016/j.immuni.2016.04.005 S1074-7613(16)30110-8 trying2... trying... trying2...
Brain Endothelial- and Epithelial-Specific Interferon Receptor Chain 1 Drives Virus-Induced Sickness Behavior and Cognitive Impairment. | LitMetric
Sickness behavior and cognitive dysfunction occur frequently by unknown mechanisms in virus-infected individuals with malignancies treated with type I interferons (IFNs) and in patients with autoimmune disorders. We found that during sickness behavior, single-stranded RNA viruses, double-stranded RNA ligands, and IFNs shared pathways involving engagement of melanoma differentiation-associated protein 5 (MDA5), retinoic acid-inducible gene 1 (RIG-I), and mitochondrial antiviral signaling protein (MAVS), and subsequently induced IFN responses specifically in brain endothelia and epithelia of mice. Behavioral alterations were specifically dependent on brain endothelial and epithelial IFN receptor chain 1 (IFNAR). Using gene profiling, we identified that the endothelia-derived chemokine ligand CXCL10 mediated behavioral changes through impairment of synaptic plasticity. These results identified brain endothelial and epithelial cells as natural gatekeepers for virus-induced sickness behavior, demonstrated tissue specific IFNAR engagement, and established the CXCL10-CXCR3 axis as target for the treatment of behavioral changes during virus infection and type I IFN therapy.
Publication Analysis
Top Keywords
endothelial- epithelial-specific
4
Similar Publications
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!